JPMorgan Chase & Co. Raises Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

JPMorgan Chase & Co. lifted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 218.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 400,351 shares of the company's stock after purchasing an additional 274,641 shares during the quarter. JPMorgan Chase & Co. owned about 0.51% of Viridian Therapeutics worth $9,108,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Arizona State Retirement System increased its position in shares of Viridian Therapeutics by 14.7% during the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company's stock valued at $171,000 after purchasing an additional 1,688 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Viridian Therapeutics by 17.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company's stock valued at $318,000 after acquiring an additional 2,036 shares during the last quarter. AlphaCentric Advisors LLC raised its stake in shares of Viridian Therapeutics by 20.0% in the third quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company's stock valued at $341,000 after acquiring an additional 2,500 shares during the period. DCF Advisers LLC lifted its holdings in shares of Viridian Therapeutics by 22.4% in the 2nd quarter. DCF Advisers LLC now owns 17,750 shares of the company's stock worth $231,000 after acquiring an additional 3,250 shares during the last quarter. Finally, Quest Partners LLC boosted its stake in shares of Viridian Therapeutics by 344.0% during the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company's stock worth $79,000 after purchasing an additional 4,692 shares during the period.

Analyst Ratings Changes

A number of analysts recently weighed in on VRDN shares. TD Cowen initiated coverage on shares of Viridian Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating on the stock. BTIG Research raised their price target on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a "buy" rating in a research note on Thursday, September 26th. Royal Bank of Canada upped their price objective on Viridian Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Tuesday, December 17th. HC Wainwright reiterated a "buy" rating and set a $34.00 target price on shares of Viridian Therapeutics in a research report on Monday, December 16th. Finally, Wells Fargo & Company restated an "equal weight" rating and issued a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, Viridian Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $35.70.

Viridian Therapeutics Stock Down 5.1 %

NASDAQ:VRDN traded down $0.91 during trading hours on Tuesday, reaching $16.86. The company's stock had a trading volume of 1,647,981 shares, compared to its average volume of 1,660,335. The stock has a 50 day moving average price of $20.31 and a two-hundred day moving average price of $18.99. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The company has a market capitalization of $1.34 billion, a P/E ratio of -3.91 and a beta of 1.13. Viridian Therapeutics, Inc. has a 12 month low of $11.40 and a 12 month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.04). Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.08 million. Equities analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.